Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720

EPMA Journal

Volumn 5, Issue 1, 2014, Pages

  Baldacchino, Shawn ^a   Saliba, Christian ^a   Petroni, Vanessa ^a   Fenech, Anthony G ^a   Borg, Nigel ^a   Grech, Godfrey ^a  

^a UNIVERSITY OF MALTA   (Malta)

Author keywords

Personalised medicine; PP2A; Predictive biomarkers; Therapeutic groups

Indexed keywords

COMPLEMENTARY DNA; ESTROGEN RECEPTOR; FINGOLIMOD; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; RAPAMYCIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INCIDENCE; CANCER RESISTANCE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME REGULATION; GENE MUTATION; HUMAN; HUMAN CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN TARGETING; RNA EXTRACTION; SIGNAL TRANSDUCTION;

EID: 84905035215     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/1878-5085-5-3     Document Type: Article

References (56)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
3. Schnitt SJ: Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol 2010, 23:S60-S64.
4. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN: Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009, 7(1-2):4-13.
5. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY, Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 2007, 98(12):1889-1892.
6. Leevers SJ, Vanhaesebroeck B, Waterfield MD: Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr Opin Cell Biol 1999, 11(2):219-225.
7. Saito K, Scharenberg AM, Kinet JP: Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem 2001, 276(19):16201-16206.
8. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT: Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science 1997, 277(5325):567-570.
9. Tang B, Mano H, Yi T, Ihle JN: Tec kinase associates with c-kit and is tyrosine phosphorylated and activated following stem cell factor binding. Mol Cell Biol 1994, 14(12):8432-8437.
10. Russillo M, Di Benedetto A, Metro G, Ferretti G, Papaldo P, Cognetti F, Mottolese M, Fabi A: Assessment of PTEN and PI3K status in primary breast cancer and corresponding metastases: is it worthwhile? J Clin Oncol 2011, 29(20):2834-2835. author reply 2835.
11. Liu L, Chen L, Luo Y, Chen W, Zhou H, Xu B, Han X, Shen T, Huang S: Rapamycin inhibits IGF-1 stimulated cell motility through PP2A pathway. PLoS One 2010, 5(5):e10578.
12. Peyssonnaux C, Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001, 93(1-2):53-62.
13. Silverstein AM: Actions of PP2A on the MAP kinase pathway and apoptosis are mediated by distinct regulatory subunits. Proc Natl Acad Sci 2002, 99(7):4221-4226.
14. Grech G, Blazquez-Domingo M, Kolbus A, Bakker WJ, Mullner EW, Beug H, von Lindern M: Igbp1 is part of a positive feedback loop in stem cell factor-dependent, selective mRNA translation initiation inhibiting erythroid differentiation. Blood 2008, 112(7):2750-2760.
15. Calin GA, Iasio MG, Caprini E, Vorechovsky I, Natali PG, Sozzi G, Croce CM, Barbanti-Brodano G, Russo G, Negrini M: Low frequency of alterations of the a (PPP2R1A) and ß (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000, 19:1191-1195.
16. Ruediger R, Ruiz J, Walter G: Human cancer-associated mutations in the Aa subunit of protein phosphatase 2A increase lung cancer incidence in Aa knock-in and knockout mice. Mol Cell Biol 2011, 31(18):3832-3844.
17. Janssens V, Goris J, Van Hoof C: PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005, 15(1):34-41.
18. Wang SS, Esplin ED, Li JL, Huang L, Evans GA: Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998, 282(5387):284-287.
19. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, Saji S: Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000, 47(2):268-271.
20. Chou H-C, Chen C-H, Lee H-S, Lee C-Z, Huang G-T, Yang P-M, Lee PH, Sheu JC: Alterations of tumour suppressor gene PPP2R1B in hepatocellular carcinoma. Cancer Lett 2007, 253(1):138-143.
21. Stebbing J, Lit LC, Zhang H, Darrington RS, Melaiu O, Rudraraju B, Giamas G: The regulatory roles of phosphatases in cancer. Oncogene 2013. doi:10.1038/onc.2013.80.
22. Sablina AA, Chen W, Arroyo JD, Corral L, Hector M, Bulmer SE, DeCaprio JA, Hahn WC: The tumor suppressor PP2A Aß regulates the RalAGTPase. Cell 2007, 129(5):969-982.
23. Wong LL, Zhang D, Chang CF, Koay ES: Silencing of the PP2A catalytic subunit causes HER-2/neu positive breast cancer cells to undergo apoptosis. Exp Cell Res 2010, 316(20):3387-3396.
24. Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res 2008, 10(6): R101.
25. Gewinner C, Wang ZC, Richardson A, Teruya-Feldstein J, Etemadmoghadam D, Bowtell D, Barretina J, Lin WM, Rameh L, Salmena L, Pandolfi PP, Cantley LC: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer cell 2009, 16(2):115-125.
26. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM: Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol 2007, 21(8):1905-1923.
27. Ugi S, Imamura T, Maegawa H, Egawa K, Yoshizaki T, Shi K, Obata T, Ebina Y, Kashiwagi A, Olefsky JM: Protein phosphatase 2A negatively regulates insulin's metabolic signaling pathway by inhibiting Akt (protein kinase B) activity in 3 T3-L1 adipocytes. Mol Cell Biol 2004, 24(19):8778-8789.
28. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, Powell SN, Yang Q: Negative regulation of AKT activation by BRCA1. Cancer Res 2008, 68(24):10040-10044.
29. Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R: Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998, 2(3):317-328.
30. Filonenko V, Tytarenko R, Azatjan S, Savinska L, Gaydar Y, Gout I, Usenko VS, Lyzogubov VV: Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors. Exp Oncol 2004, 26(4):294-299.
31. Zhou X: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10(20):6779-6788.
32. Stål O, Pérez-Tenorio G, Åkerberg L, Olsson B, Nordenskjöld B, Skoog L, Rutqvist LE: Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003, 5(2):R37-R44.
33. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012, 490(7418):61-70.
34. Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, Kallioniemi O, Thézenas S, Westermarck J: CIP2A Is associated with human breast cancer aggressivity. Clin Cancer Res 2009, 15(16):5092-5100.
35. Junttila MR, Puustinen P, Niemelä M, Ahola R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, Lu SL, Lin S, Chan EK, Wang XJ, Grènman R, Kast J, Kallunki T, Sears R, Kähäri VM, Westermarck J: CIP2A Inhibits PP2A in human malignancies. Cell 2007, 130(1):51-62.
36. Carlson SG, Eng E, Kim EG, Perlman EJ, Copeland TD, Ballermann BJ: Expression of SET, an inhibitor of protein phosphatase 2A, in renal development and Wilms' tumor. J Am Soc Nephrol 1998, 9:1873-1880.
37. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, Antipin Y, Reva B, Goldberg AP, Sander C, Schultz N: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discovery 2012, 2(5):401-404.
38. Flicek P, Ahmed I, Amode MR, Barrell D, Beal K, Brent S, Carvalho-Silva D, Clapham P, Coates G, Fairley S, Fitzgerald S, Gil L, García-Girón C, Gordon L, Hourlier T, Hunt S, Juettemann T, Kähäri AK, Keenan S, Komorowska M, Kulesha E, Longden I, Maurel T, McLaren WM, Muffato M, Nag R, Overduin B, Pignatelli M, Pritchard B, Pritchard E, et al: Ensembl 2013. Nucleic Acids Res 2013, 41(D1):D48-D55.
39. Wang J, Li W, Li L, Yu X, Jia J, Chen C: CIP2A is over-expressed in acute myeloid leukaemia and associated with HL60 cells proliferation and differentiation. Int J Lab Hematol 2011, 33(3):290-298.
40. Böckelman C, Lassus H, Hemmes A, Leminen A, Westermarck J, Haglund C, Bützow R, Ristimäki A: Prognostic role of CIP2A expression in serous ovarian cancer. Br J Cancer 2011, 105(7):989-995.
41. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, Lin CC, Hsu YN, Wang HW, Chen KF: CIP2A Is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012, 16(5):1037-1047.
42. Vaarala MH, Väisänen MR, Ristimäki A: CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res 2010, 29(1):136.
43. Laine A: The Role of an Oncoprotein CIP2a in Breast Carcinoma. Turku: University of Turku; 2013.
44. Niemelä M, Kauko O, Sihto H, Mpindi JP, Nicorici D, Pernilä P, Kallioniemi OP, Joensuu H, Hautaniemi S, Westermarck J: CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes. Oncogene 2012, 31(39):4266-4278.
45. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, Mao H, Chang JS, Galietta A, Uttam A, Roy DC, Valtieri M, Bruner-Klisovic R, Caligiuri MA, Bloomfield CD, Marcucci G, Perrotti D: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8(5):355-368.
46. Kong M, Ditsworth D, Lindsten T, Thompson CB: a4 is an essential regulator of PP2A phosphatase activity. Mol Cell 2009, 36(1):51-60.
47. Sablina, Hector M, Colpaert N, Hahn WC: Identification of PP2A complexes and pathways involved in cell transformation, Volume 70. 24th edition. ; 2010:10474-10484.
48. Feng Z, Levine AJ: The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein. Trends Cell Biol 2010, 20(7):427-434.
49. Westermarck J, Hahn WC: Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008, 14(4):152-160.
50. Chen KF, Liu CY, Lin YC, Yu HC, Liu TH, Hou DR, Chen PJ, Cheng AL: CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells. Oncogene 2010, 29(47):6257-6266.
51. Xiang, Jia, Sherris, Li, Wang, Lu D, Yang Q: Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 2011, 30(21):2443-2450.
52. Keen JC, Zhou QH, Park BH, Pettit C, Mack KM, Blair B, Brenner K, Davidson NE: Protein phosphatase 2A regulates estrogen receptor (ER) expression through modulation of ER mRNA stability. J Biol Chem 2005, 280(33):29519-29524.
53. Gorski JJ, Kennedy RD, Hosey AM, Harkin DP: The complex relationship between BRCA1 and ER in hereditary breast cancer. Clin Cancer Res 2009, 15(5):1514-1518.
54. Satheesha S, Cookson VJ, Coleman LJ, Ingram N, Madhok B, Hanby AM, Suleman CA, Sabine VS, Macaskill EJ, Bartlett JM, Dixon JM, McElwaine JN, Hughes TA: Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer. Mol Cancer 2011, 10(1):19.
55. Golubnitschaja O, Costigliola V, EPMA: General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European association for predictive, preventive and personalised medicine. EPMA J 2012, 3(1):14.
56. Golubnitschaja O, Yeghiazaryan K, Costigliola V, Trog D, Braun M, Debald M, Kuhn W, Schild HH: Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? EPMA J 2013, 4(1):6.